Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renamezin in Chronic Renal Failure
NCT02681991Phase 4Completed
- Sponsor
- Daewon Pharm
- Start
- Jan 2016
- Primary completion
- Sep 2016
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Renamezin in chronic kidney disease (CKD), sponsored by Daewon Pharm. Primary endpoint: Change from baseline of Indoxyl sulfate at 8 weeks. Started Jan 2016; status: completed.
02
Drugs
Renamezin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02681991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681991.